News | May 01, 2025
Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals
Alembic Pharmaceuticals commissions new facility at Pithampur
Alembic Pharmaceuticals commissions new facility at Pithampur
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
He is an experienced professional in the pharmaceutical industry with about 30 years of progressive experience
Divalproex Sodium Delayed-Release Capsules USP, 125 mg have an estimated market size of US$ 61.1 million for twelve months ending September 2024 according to IQVIA
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander
US Generics grew 5% to Rs. 467 Crores for the quarter
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Lupin's Pithampur Unit-1 gets Form 483 from USFDA with 3 observations
Subscribe To Our Newsletter & Stay Updated
